The Guardian profiles Sr. Nora Nash

The Guardian, heralded for its independent and investigative journalism, ran a feature story on Sr. Nora Nash, O.S.F.: Sister act: how a Philadelphia nun faced up to Wall Street. Sr. Nora, a member of the Sisters of St. Francis of Philadelphia, engages in the work of corporate social responsibility through Philadelphia Area Coalition for Responsible Investment (PACRI) and ICCR.

The Guardian’s article is excellent in its outline of why and how a religious community engages in CSR work and offers considerable detail about the breadth of issues that Sr. Nora and her colleagues take on as well as significant detail about the shape of those efforts with Wells Fargo and Kroger. The Guardian interviewed not only Sr. Nora’s colleagues in CSR work but also got Kroger’s communication chief to speak about the experience of working with faith-based investors.

Please, visit the article. Perhaps you may even share it with others who may wish to learn more about socially responsible investment. Again, the article is found here: https://www.theguardian.com/us-news/2017/dec/17/philadelphia-nuns-capitalism-activism

Investors say executive pay packages at pharma may incentivize drug pricing risks

Today, the ICCR published a press release about resolutions filed with five U.S. pharmaceutical companies. SGI members are co-filers on each of the five resolutions. These resolutions are important components of SGI’s activity this year in health. The resolutions can be described as tools to gain insight into how executive compensation aligns with the values, vision, and business strategy of the companies.

This post will be updated with media coverage:

The press release is shared in full below.

Investors say executive pay packages at pharma may incentivize drug pricing risks

DATE:
Dec 13th 2017

In resolutions at five U.S. drug makers, investors request a review of compensation policies that may drive senior execs to ignore the long-term business risks of skyrocketing drug costs.

NEW YORK, NY, Wednesday, December 13, 2017 – Investors today announced they have filed resolutions at five major pharmaceutical companies asking for information about how well executive pay incentives mitigate long-term financial risks associated with mounting public concerns over the affordability of prescription medicines.

The investors are all members of the Interfaith Center on Corporate Responsibility (ICCR), a shareholder coalition that has been engaging the pharma sector for decades on drug access and affordability. In the resolutions, the investors argue that an executive compensation incentive program reliant on revenue growth solely from drug price increases is a risky and unsustainable strategy.

The resolution specifically requests a report on the extent to which risks related to public concern over drug pricing strategies are reflected in executive compensation policies, plans and programs. Read the full resolution text here. The five companies receiving the resolutions are Abbvie, Amgen, Biogen, Bristol Myers Squibb, and Eli Lilly. ICCR members also filed a separate but similar resolution at Pfizer and Vertex requesting a report on the business risks from rising pressure to contain U.S. prescription drug prices.

“As investors in these companies, we are concerned that misaligned incentive pay may encourage executives to sacrifice long-term, organic growth from drug discovery for short-term, ‘quick fix’ strategies that may pose business risks,” said Meredith Miller of the UAW Retiree Medical Benefits Trust.

Public anxiety over drug prices has soared in recent years as millions of Americans struggle to afford the essential medicines needed to maintain their health. Scandals over excessive price hikes at several pharma companies have made the pharma industry the target of Congressional hearings, law suits, denials of coverage from insurers and ballot initiatives in several states which would force manufacturers to negotiate the prices of key medicines with government agencies such as Medicare and Medicaid.

Against this backdrop, the investors say, companies need to prove to their investors and to the public that they are doing everything possible to control drug prices in order to manage business and brand risk. The investors view executive incentive programs as a governance tool designed to ensure adequate oversight of risk and alignment of corporate strategies with mission.

Said Donna Meyer of Mercy Investment Services, “The increased scrutiny around drug pricing and how it is being managed by pharma management has had reputational consequences for the entire industry. Our resolution request is very straightforward: an evaluation of how these concerns are being integrated into corporate governance structures. To the degree that executive incentives reflect a company’s mission and growth strategies, this is clearly a critical and material issue for investors.”

“Our goal is to better understand what oversight these pharmaceutical company boards are exercising when executive incentives are tied so closely to profits,” said Cathy Rowan, who represents Trinity Health as a member of ICCR. “When these profits appear to be derived wholly from price hikes, it raises concerns among those of us who care about access to, and the affordability of, medicines — particularly for vulnerable populations like women, children and seniors.”

Investors are expected to vote on the resolutions at each company’s 2018 annual meeting of shareholders.

SGI Webinar Recording: Navigating the ICCR and SGI Websites

During our November member meeting, we announced our plan to conduct quarterly webinars to educate SGI Members on ICCR issues and processes. At the time, we agreed to start with an orientation of ICCR’s and SGI’s websites. We were fortunate to have Julie Wokaty of ICCR join us to give us a tour of ICCR’s website and Chris Cox to do the same for SGI’s website.

A recording of the webinar can be found here. The slides from Chris’ presentation on using social media for corporate social responsibility are here.

We will maintain an index of webinars and links to the recordings on our Resources page.

Fr. Mike Crosby receives ICCR Legacy Award

On September 28, Fr. Dan Crosby, O.F.M. Cap., accepted ICCR’s Legacy Award on behalf of his brother and SGI’s founder, Fr. Mike Crosby, O.F.M. Cap., together with Sr. Patricia Daly, O.P., Tri-State Coalition for Responsible Investment.  The event was held at New York’s historic Riverside Church.  Fr. Dan Crosby accepted his brother’s award with humility and gratitude in the same way Mike approached his work. “The corporate executives whom Mike engaged always respected him because he was never trying to attack them,” he said. “He was just trying always to speak the truth in love.”

ICCR informed Fr. Crosby that he was receiving this year’s Legacy Award shortly after he began hospice treatment last June.   Fr. Mike shared at the time, “I want to finish my remarks with a word to the young people in the audience. You are the ones that inspired me to do this work. It was for you and future generations that inspired me. It is now your turn to carry this work forward to bring good news to the poor and God’s creation. God bless you all.”

Donations in honor of Fr. Mike Crosby

We have received inquiries about how a person might honor Fr. Mike Crosby, O.F.M., Cap., who passed away on August 5th. ICCR, for example, has encouraged its members to donate to SGI, and we are grateful for the support. They wrote:

Many of you know that Mike was instrumental in helping to recruit Catholic congregations into the ICCR fold and organizing them under regional coalitions for responsbile investment or “CRIs”. Mike himself was the Executive Director of the Midwest CRI also known as the Seventh Generation Interfaith CRI.

Seventh Generation Interfaith CRI is a 501(c)(3) public charity almost entirely based on member dues. If you would like to contribute to its mission in memory of Fr. Crosby, please, make your tax deductible check out to Seventh Generation Interfaith Inc. and send it to the following address:

Seventh Generation Interfaith Coalition for Responsible Investment
1015 N. 9th Street
Milwaukee, WI 53233